Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors

BACKGROUND: Drugs inhibiting the mammalian target of rapamycin (mTOR) are approved in the treatment of renal cell carcinoma (RCC), but resistance inevitably emerges. Proposed escape pathways include increased phosphorylation of Akt, which can be down regulated by histone deacetylase (HDAC) inhibitor...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Invest New Drugs
Huvudupphovsmän: Zibelman, Matthew, Wong, Yu-Ning, Devarajan, Karthik, Malizzia, Lois, Corrigan, Alycia, Olszanski, Anthony J., Denlinger, Crystal S., Roethke, Susan K., Tetzlaff, Colleen H., Plimack, Elizabeth R.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2015
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4573837/
https://ncbi.nlm.nih.gov/pubmed/26091915
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-015-0261-3
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk